title: Simultaneous control of third-degree graft-versus-host disease and prevention of recurrence of juvenile myelomonocytic leukemia (JMML) with 6-mercaptopurine following fulminant JMML relapse early after KIR-mismatched bone marrow transplantation.
abstract: The authors describe a young boy with juvenile myelomonocytic leukemia (JMML) who relapsed 45 days after HLA and killer immunoglobulin-like receptor (KIR) mismatched unrelated donor bone marrow transplant (MMUD-BMT) and subsequently developed life-threatening graft-versus-host disease (GvHD). Treatment with 6-mercaptopurine (6-MP) appeared to control severe GvHD and possibly prevented recurrence of leukemic relapse.
authors.affiliation: Department of Pediatrics, University of Erlangen-Nurnberg, Erlangen, Germany. Daniel.Stachel@kinder.imed.uni-erlangen.de
authors.forename: Daniel K
authors.initials: DK
authors.lastname: Stachel
authors.forename: Alfred
authors.initials: A
authors.lastname: Leipold
authors.forename: Michaela
authors.initials: M
authors.lastname: Kuhlen
authors.forename: Chara
authors.initials: C
authors.lastname: Gravou-Apostolatou
authors.forename: Kaimo
authors.initials: K
authors.lastname: Hirv
authors.forename: Peter
authors.initials: P
authors.lastname: Bader
authors.forename: Charlotte M
authors.initials: CM
authors.lastname: Niemeyer
authors.forename: Jörn D
authors.initials: JD
authors.lastname: Beck
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Holter
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D002066:Busulfan / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D006086:Graft vs Host Disease / Q000188:drug therapy*; D020544:Graft vs Leukemia Effect; D015235:HLA-B Antigens / Q000235:genetics; D059950:HLA-B52 Antigen; D015236:HLA-C Antigens / Q000235:genetics; D018380:Hematopoietic Stem Cell Transplantation; D006648:Histocompatibility; D006801:Humans; D007223:Infant; D015479:Leukemia, Myelomonocytic, Acute / Q000188:drug therapy* / Q000628:therapy; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D015122:Mercaptopurine / Q000627:therapeutic use*; D011971:Receptors, Immunologic / Q000235:genetics*; D054340:Receptors, KIR; D012074:Remission Induction; D055502:Secondary Prevention; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous
chemical_list: D000964:Antimetabolites, Antineoplastic; D015235:HLA-B Antigens; D059950:HLA-B52 Antigen; D015236:HLA-C Antigens; C110748:HLA-C*12 antigen; C446264:HLA-C*15 antigen; C040178:HLA-C*70 antigen; D011971:Receptors, Immunologic; D054340:Receptors, KIR; D003520:Cyclophosphamide; D015122:Mercaptopurine; D002066:Busulfan; D008558:Melphalan